» Articles » PMID: 23023832

MRI Assessment of Percutaneous Ablation of Liver Tumors: Value of Subtraction Images

Overview
Date 2012 Oct 2
PMID 23023832
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the value of subtraction images when using MRI to assess liver tumors treated with percutaneous ablation.

Materials And Methods: Following percutaneous ablation of 35 liver tumors, two abdominal radiologists, blinded to outcomes, independently reviewed follow-up MRI examinations for tumoral enhancement suggestive of residual/recurrent tumor and rated their confidence level. After one year, the readers reviewed the same examinations with added subtraction images. Accuracy of the detection of residual/recurrent tumor and contrast-to-noise ratios (CNR; for tumoral enhancement-to-liver, tumoral enhancement-to-ablation zone, and ablation zone-to-liver) were calculated with and without subtraction images and compared using Wilcoxon signed rank test. Interobserver variability was computed using Kappa (κ) statistics.

Results: Residual/recurrent tumor was present in 8 (23.5%) of 34 tumors. Accuracy of detecting residual/recurrent tumor with subtraction images and interobserver agreement (κ = 0.72, good) were better than accuracy of detecting residual/recurrent tumor and interobserver agreement (κ = 0.57, moderate) of enhanced MR images without subtraction. Mean CNR of subtraction images was significantly higher than that of enhanced MR images for tumoral enhancement-to-liver (0.2 ± 5 versus 11.6 ± 14.4, P = 0.03), tumoral enhancement-to-ablation zone (10.1 ± 12.5 versus 34.4 ± 29.4, P = 0.02), and ablation zone-to-liver (11.8 ± 13.3 versus 102.5 ± 238.4, P = 0.03).

Conclusion: When using MRI, subtraction images help both detect and exclude residual/recurrent tumor following percutaneous liver ablations.

Citing Articles

Radiofrequency Ablation of Hepatic Tumor: Subjective Assessment of the Perilesional Vascular Network on Contrast-Enhanced Computed Tomography Before and After Ablation Can Reliably Predict the Risk of Local Recurrence.

Yedururi S, Terpenning S, Gupta S, Fox P, Martin S, Conrad C J Comput Assist Tomogr. 2017; 41(4):607-613.

PMID: 28722702 PMC: 5520651. DOI: 10.1097/RCT.0000000000000562.


Evolutionary magnetic resonance appearance of renal cell carcinoma after percutaneous cryoablation.

Lee H, Chung H, Wang H, Shen S, Chang Y, Chen C Br J Radiol. 2016; 89(1065):20160151.

PMID: 27401340 PMC: 5124922. DOI: 10.1259/bjr.20160151.


Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Ellingson B, Kim H, Woodworth D, Pope W, Cloughesy J, Harris R Radiology. 2014; 271(1):200-10.

PMID: 24475840 PMC: 4263651. DOI: 10.1148/radiol.13131305.